Two of Proteostasis’ Three Cystic Fibrosis Therapies Are in Clinical Trials, and the Third Is Heading for Trials
Two of the three therapies that Proteostasis Therapeutics has developed to correct the underlying problem in cystic fibrosis are going through clinical trials and a third is heading for trials, the company reports. That underlying problem is a mutation in a gene known as the cystic fibrosis transmembrane conductance regulator, or CFTR. It produces…